Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials

Background: Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson’s disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting. Objectives: To assess the safe...

Descrición completa

Detalles Bibliográficos

Principais autores:	Maria-Ioanna Stefanou, Evangelos Panagiotopoulos, Anastasios Tentolouris, Aikaterini Theodorou, Georgia Papagiannopoulou, Athanasia Athanasaki, Panagiota-Eleni Tsalouchidou, Melpomeni Peppa, Vaia Lambadiari, Spiridon Konitsiotis, Annerose Mengel, Georgios P. Paraskevas, Nikolaos Tentolouris, Georgios Tsivgoulis
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAGE Publishing 2026-01-01
Series:	Therapeutic Advances in Neurological Disorders
Acceso en liña:	https://doi.org/10.1177/17562864251408269
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!